Molecure is applying for approval for a Phase 1 clinical trial for the compound OATD-02

Molecure applied to the president of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for authorization to start a phase I clinical trial for OATD-02, the company said.

“The planned Phase I clinical trial will be an open-label, multicentre, ascending-dose trial, for the first time in humans, to assess the safety, tolerability and antitumor activity, and to establish the maximum tolerated dose of OATD-02. The company intends to start the audit in the fourth quarter of 2022. " - we read in the announcement.

The company plans to conduct the first phase of the OATD-02 clinical trial in up to 40 patients with advanced or metastatic solid tumors, including colorectal cancer, ovarian cancer, pancreatic cancer or renal cell carcinoma. The duration of the study was planned for 24 months.

Molecure (formerly OncoArendi Therapeutics) is a biotechnology company specializing in the search, development and commercialization of new drugs for the treatment of respiratory diseases and cancer. The company has been listed on the WSE main market since April 2018.

Our privacy policy